Cirrhotic cardiomyopathy is a myocardial dysfunction that occurs in end-stage liver disease, characterized by systolic and diastolic dysfunction, cardiac structural changes, and electrophysiological abnormalities. It is a known but poorly understood complication of cirrhosis, with adverse clinical consequences for the overall health, survival, and prognosis of patients with cirrhosis. Liver dysfunction and systemic inflammatory response under portal hypertension are jointly involved in its pathogenesis. This article will review the research progress on the pathogenesis of liver cirrhosis cardiomyopathy in recent years from two aspects: elevated levels of circulating bile acids caused by liver dysfunction and systemic chronic inflammatory response under portal hypertension.